Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: A pharmacogenomic study

Cancer Research

Volumn 63, Issue 11, 2003, Pages 2782-2793

  Daoud, Sayed S ^a   Munson, Peter J ^b   Reinhold, William ^c   Young, Lynn ^b   Prabhu, Vinay V ^b   Yu, Qiang ^c   LaRose, Jihyun ^c   Kohn, Kurt W ^c   Weinstein, John N ^c   Pommier, Yves ^c  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DNA TOPOISOMERASE INHIBITOR; PROTEIN FOS; PROTEIN P53; RNA; TOPOTECAN; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; ARTICLE; CELL CYCLE; COLON CARCINOMA; CONCENTRATION RESPONSE; DNA DAMAGE; DNA MICROARRAY; GENE EXPRESSION; GENE OVEREXPRESSION; GENOTYPE; HUMAN; HUMAN CELL; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; RNA ANALYSIS;

ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOGENETICS; TOPOTECAN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0038615915     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
2. Vogelstein, B., Lane, D., and Levine, A. J. Surfing the p53 network. Nature (Lond.), 408: 307-310, 2000.
3. Ko, L. J., and Prives, C. p53: puzzle and paradigm. Genes Dev., 10: 1054-1072, 1996.
4. Colman, M. S., Afshari, C. A., and Barrett, J. C. Regulation of p53 stability and activity in response to genotoxic stress. Mutat. Res., 462: 179-188, 2000.
5. Zambetti, G., Bargonetti, J., Walker, J., Prives, C., and Levine, A. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev., 6: 1143-1152, 1992.
6. Kannan, K., Amariglio, N., Rechavi, G., Jakob-Hirsch, J., Kela, I., Kaminski, N., Getz, G., Domany, E., and Givol, D. DNA microarrays identification of primary and secondary target genes regulated by p53, Oncogene, 20: 2225-2234, 2001.
7. Ginsberg, D., Mechta, F., Yaniv, M., and Oren, M. Wild-type p53 can down modulate the activity of various promoters. Proc. Natl. Acad. Sci. USA, 8: 9979-9983, 1991.
8. Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., and Vogelstein, B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Investig., 104: 263-269, 1999.
9. Kollmannsberger, C., Mross, K., Jakob, A., Kanz, L., and Bokemeyer, C. Topotecan, a novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology (Basel), 56: 1-12, 1999.
10. Pommier, Y., Pourquier, P., Fan, Y., and Strumberg, D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochem. Biophys. Acta, 1400: 83-105, 1998.
11. Carlisle, A. J., Prabhu, V. V., Elkahloun, A., Hudson, J., Trent, J. M., Linehan, W. M., et al. Development of a prostate cDNA microarray and statistical gene expression analysis package. Mol. Carcinog., 28: 12-22, 2000.
12. Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Kohn, K. W., et al. An information-intensive approach to the molecular pharmacology of cancer. Science (Wash. DC), 275: 343-349, 1997.
13. Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., et al. A gene expression database for the molecular pharmacology of cancer. Nat. Genet., 24: 236-244, 2000.
14. Shao, R. G., Cao, C. X., Shimizu, T., O'Connor, P. M., Kohn, K. W., and Pommier, Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly by p53 function. Cancer Res., 57: 4029-4035, 1997.
15. Lastres, P., Letamendia, A., Zhang, H., Rius, C., et al. Endoglin modulates cellular responses to TGF-β1. J. Cell Biol., 133: 1109-1121, 1996.
16. Li, C., Hampson, I. N., Hampson, L., Kumar, P., et al. CD 105 antagonizes the inhibitory signaling of transforming growth factor β 1 on human vascular endothelial cells. FASEB J., 14: 55-64, 2000.
17. Sherbet, G. V., and Lakshmi, M. S. S100A4 (MTS1) calcium binding protein in cancer growth, invasion and metastasis. Anticancer Res., 18: 2415-2422, 1998.
18. Kriajevska, M., Tarabykina, S., Bronstein, I., Maitland, N., et al. Metastasis-associated Mts1 (S100A4) protein modulates protein kinase C phosphorylation of the heavy chain of nonmuscle myosin. J. Biol. Chem., 273: 9852-9856, 1998.
19. Wisdom, R. AP-1: One switch for many signals. Exp. Cell Res., 253: 180-185, 1999.
20. Bartke, T., Siegmund, D., Peters, N., Reichwein, M., Henkler, F. Scheurich, P, and Wajant, H. p53 upregulates cFLIP inhibits transcription of NF-κB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. Oncogene, 20: 571-580, 2001.
21. Desagher, S., Osen-Sand, A., Montessuit, S., Magnenat, E., Vilbois, F., Hochmann, A., et al. Phosphorylation of bid by casein kinase I and II regulates its cleavage by caspase 8. Mol. Cell, 8: 601-611, 2001.
22. Lin, X., and Gelman, I. H. Calmodulin and cyclin D anchoring sites on the Src-suppressed C kinase substrate, SSeCKS. Biochim. Biophys. Res. Commun., 290: 1368-1375, 2002.
23. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. p53 mutation in human cancers. Science (Wash. DC), 253: 49-53, 1991.
24. Lowe, S. W., Bodis, S., McClatchey, A., et al. p53 status and the efficacy of cancer therapy. Science (Wash. DC), 266: 807-810, 1994.
25. Yu, J., Zhang, L., Hwang, P. M., Rago, C., Kinzler, K. W., and Vogelstein, B. Identification and classification of p53-regulated genes. Proc. Natl. Acad. Sci. USA, 95: 14517-14522, 1999.
26. Zhao, R., Gish, K., Murphy, M., Yin, Y., Notterman, D., Hoffman, W. H., Tom, E., Mack, D. H., and Levine, A. J. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev., 14: 981-993, 2000.
27. Wang, L., Wu, Q., Qiu, P., Mirza, A., McGuirk, M., Kirschmeier, P., et al. Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches. J. Biol. Chem., 276: 43604-43610, 2001.
28. Cao, C., Ren, X., Kharbanda, S., Koleske, A., Prasad, K. V., and Kufe, D. The ARG tyrosine kinase interacts with Siva-1 in the apoptotic response to oxidative stress. J. Biol. Chem., 276: 11465-11468, 2001.
29. Donato, R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell Biol., 33: 637-668, 2001.
30. Scotto, C., Deloulme, J. C., Rousseau, D., Chambaz, E., and Baudier, J. Calcium and S100 B regulation of p53-dependent cell growth arrest and apoptosis. Mol. Cell. Biol., 18: 4272-4281, 1998.
31. Grigorian, M., Andresen, S., Tulchinsky, E., Kriajevska, M., Carlberg, C., Kruse, C., Cohen, M., et al. Tumor suppressor p53 protein in a new target for the metastasis-associated Mts1/S100A4 protein: functional consequences of their interaction. J. Biol. Chem., 276: 22699-22708, 2001.
32. Kriajevska, M., Fischer-Larsen, M., Moertz, E., Vorm, O., Tulchinsky, E., Grigorian, M., Ambartsumian, N., and Lukanidin, E. Liprin β 1, a member of the family of LAR transmembrane tyrosine phosphatase-interacting proteins, is a new target for the metastasis-associated protein S100A4 (Mts1). J. Biol. Chem., 277: 5229-5235, 2002.
33. Ravagnan, L., Gurbuxani, S., Susin, S. A., Maisse, C., Daugas, E., Zamzami, N., Mak, T., Jaattela, M., Penninger, J. M., Garrido, C., and Kroemer, G. Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat. Cell Biol., 3: 839-843, 2001.